Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?

benzinga.com/general/biotech/25/05/45596782/bicara-therapeutics-shares-sink-over-43-on-mixed-phase-1-1b-trial-results-whats-going-on

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares are trading lower Friday following the release of updated interim data from its Phase 1/1b trial of ficerafusp alfa in combination with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma.
What To…

This story appeared on benzinga.com, 2025-05-23 20:46:02.
The Entire Business World on a Single Page. Free to Use →